Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification

Kym Snell, Douglas Ward, Naheema Gordon, James Goldsmith, Andrew Sutton, Prashant Patel, Nicholas James, Maurice Zeegers, Kar Cheng, Richard Bryan

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)
120 Downloads (Pure)


Objectives: To investigate whether elevated urinary HAI-1, EpCAM and EGFR are independent prognostic biomarkers within non-muscle-invasive bladder cancer (NMIBC) patients, and have utility for risk stratification to facilitate treatment decisions.

Results: After accounting for EAU risk group in NMIBC patients, the risk of BC-specific death was 2.14 times higher (95% CI: 1.08 to 4.24) if HAI-1 was elevated and 2.04 times higher (95% CI: 1.02 to 4.07) if EpCAM was elevated. The majority of events occurred in the high-risk NMIBC group and this is where the biggest difference is seen in the survival curves when plotted for EAU risk groups separately. In MIBC patients, being elevated for any of the three biomarkers was significantly associated with BC-specific mortality after accounting for other risk factors, HR = 4.30 (95% CI: 1.85 to 10.03).

Patients and Methods: Urinary levels of HAI-1, EpCAM and EGFR were measured by ELISA in 683 and 175 patients with newly-diagnosed NMIBC and MIBC, respectively, recruited to the Bladder Cancer Prognosis Programme. Associations between biomarkers and progression, BC-specific mortality and all-cause mortality were evaluated using univariable and multivariable Cox regression models, adjusted for European Association of Urology (EAU) NMIBC risk groups. The upper 25% of values for each biomarker within NMIBC patients were considered as elevated. Exploratory analyses in urine from MIBC patients were also undertaken.

Conclusion: Urinary HAI-1 and EpCAM are prognostic biomarkers for NMIBC patients. These biomarkers have potential to guide treatment decisions for high-risk NMIBC patients. Further analyses are required to define the roles of HAI-1, EpCAM and EGFR in MIBC patients.
Original languageEnglish
Pages (from-to)25244-25253
Number of pages10
Issue number38
Publication statusPublished - 18 May 2018


Dive into the research topics of 'Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification'. Together they form a unique fingerprint.
  • Bladder cancer prognosis

    Bryan, R. & Ward, D., 2 Jun 2016, IPC No. G01N 33/574 (2006.01), G01N 33/68 (2006.01), Patent No. WO/2016/083832, Priority date 28 Nov 2014, Priority No. US 62/085,433

    Research output: Patent

    Open Access

Cite this